Theodore Logan

  • 6527 Citations
  • 36 h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

2020

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

Dudek, A. Z., Liu, L. C., Gupta, S., Logan, T. F., Singer, E. A., Joshi, M., Zakharia, Y. N., Lang, J. M., Schwarz, J. K., Al-Janadi, A. & Alva, A. S., Apr 10 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 11, p. 1138-1145 8 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

Timmerman, J., Herbaux, C., Ribrag, V., Zelenetz, A. D., Houot, R., Neelapu, S. S., Logan, T., Lossos, I. S., Urba, W., Salles, G., Ramchandren, R., Jacobson, C., Godwin, J., Carpio, C., Lathers, D., Liu, Y., Neely, J., Suryawanshi, S., Koguchi, Y. & Levy, R., May 1 2020, In : American Journal of Hematology. 95, 5, p. 510-520 11 p.

Research output: Contribution to journalArticle

2019

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Voss, M. H., Bhatt, R. S., Vogelzang, N. J., Fishman, M., Alter, R. S., Rini, B. I., Beck, J. T., Joshi, M., Hauke, R., Atkins, M. B., Burgess, E., Logan, T. F., Shaffer, D., Parikh, R., Moazzam, N., Zhang, X., Glasser, C., Sherman, M. L. & Plimack, E. R., Jul 15 2019, In : Cancer. 125, 14, p. 2400-2408 9 p.

Research output: Contribution to journalArticle

2 Scopus citations
2018

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Clark, J. I., Singh, J., Ernstoff, M. S., Lao, C. D., Flaherty, L. E., Logan, T. F., Curti, B., Agarwala, S. S., Taback, B., Cranmer, L., Lutzky, J., Luna, T. L., Aung, S. & Lawson, D. H., Jul 27 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 76.

Research output: Contribution to journalArticle

7 Scopus citations

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma

Tarhini, A. A., Frankel, P., Ruel, C., Ernstoff, M. S., Kuzel, T. M., Logan, T. F., Khushalani, N. I., Tawbi, H. A., Margolin, K. A., Awasthi, S., Butterfield, L. H., McDermott, D., Chen, A., Lara, P. N. & Kirkwood, J. M., Nov 15 2018, In : Cancer. 124, 22, p. 4332-4341 10 p.

Research output: Contribution to journalArticle

2 Scopus citations

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma

Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T. F., Hauschild, A., Lebbé, C., Chen, L., Kim, J. J., Gansert, J., Andtbacka, R. H. I. & Kaufman, H. L., Jun 10 2018, In : Journal of Clinical Oncology. 36, 17, p. 1658-1667 10 p.

Research output: Contribution to journalArticle

178 Scopus citations
2017

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: Data from the PROCLAIMSM registry

Curti, B., Daniels, G. A., McDermott, D. F., Clark, J. I., Kaufman, H. L., Logan, T. F., Singh, J., Kaur, M., Luna, T. L., Gregory, N., Morse, M. A., Wong, M. K. K. & Dutcher, J. P., Dec 19 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 102.

Research output: Contribution to journalArticle

8 Scopus citations

Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M. & Levy, R., Apr 15 2017, In : Clinical Cancer Research. 23, 8, p. 1929-1936 8 p.

Research output: Contribution to journalArticle

89 Scopus citations
2016

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Alva, A., Daniels, G. A., Wong, M. K. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G., Logan, T. F., Hauke, R. J., Curti, B., Kirkwood, J. M., Gonzalez, R., Amin, A., Fishman, M., Agarwal, N., Lowder, J. N., Hua, H., Aung, S. & 1 others, Dutcher, J. P., Dec 1 2016, In : Cancer Immunology, Immunotherapy. 65, 12, p. 1533-1544 12 p.

Research output: Contribution to journalArticle

36 Scopus citations

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial

Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., Lusk, C. M., Oberg, S. & George, D. J., Mar 1 2016, In : The lancet oncology. 17, 3, p. 378-388 11 p.

Research output: Contribution to journalArticle

165 Scopus citations

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., Buchbinder, E. I., Berghorn, E., Ruisi, M., Kong, G., Jiang, J., Horak, C. & Hodi, F. S., Jul 1 2016, In : The lancet oncology. 17, 7, p. 943-955 13 p.

Research output: Contribution to journalArticle

177 Scopus citations
2015

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: Clinical implications for targeted therapy

Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K., Sen, J. D., Malek, A. J., Katona, T. M., Warren, S., Logan, T. F., Fecher, L. A. & Cheng, L., Apr 8 2015, In : Modern Pathology. 28, 4, p. 480-486 7 p.

Research output: Contribution to journalArticle

20 Scopus citations

Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., Margolin, K. A., Plimack, E. R., Lambert, A. M., Waxman, I. M. & Hammers, H. J., May 1 2015, In : Journal of Clinical Oncology. 33, 13, p. 1430-1437 8 p.

Research output: Contribution to journalArticle

607 Scopus citations

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., Tcherepanova, I. Y., DeBenedette, M. A., Williams, W. L., Plessinger, D. C., Nicolette, C. A. & Figlin, R. A., Apr 21 2015, In : Journal for ImmunoTherapy of Cancer. 3, 1, 14.

Research output: Contribution to journalArticle

100 Scopus citations

The high-dose aldesleukin "select" trial: A trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

McDermott, D. F., Cheng, S. C., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., Appleman, L., Wong, M. K. K., Khushalani, N. I., Oleksowicz, L., Vaishampayan, U. N., Mier, J. W., Panka, D. J., Bhatt, R. S., Bailey, A. S., Leibovich, B. C. & 7 others, Kwon, E. D., Kabbinavar, F. F., Belldegrun, A. S., Figlin, R. A., Pantuck, A. J., Regan, M. M. & Atkins, M. B., Feb 1 2015, In : Clinical Cancer Research. 21, 3, p. 561-568 8 p.

Research output: Contribution to journalArticle

79 Scopus citations
4 Scopus citations
2014

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: A phase 1b study

Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., Kee, D., Boasberg, P., Yin, M., Chan, I., Musib, L., Choong, N., Puzanov, I. & McArthur, G. A., Aug 2014, In : The lancet oncology. 15, 9, p. 954-965 12 p.

Research output: Contribution to journalArticle

177 Scopus citations

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma

Lam, E. T., Wong, M. K. K., Agarwal, N., Redman, B. G., Logan, T., Gao, D., Flaig, T. W., Lewis, K., Poust, J., Monk, P., Jarkowski, A., Sendilnathan, A., Bolden, M., Kuzel, T. M. & Olencki, T., Sep 2014, In : Journal of Immunotherapy. 37, 7, p. 360-365 6 p.

Research output: Contribution to journalArticle

10 Scopus citations
2013

Foretinib (XL880): C-MET inhibitor with activity in papillary renal cell cancer

Logan, T. F., Apr 1 2013, In : Current oncology reports. 15, 2, p. 83-90 8 p.

Research output: Contribution to journalArticle

17 Scopus citations

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L. H., Laubscher, K. H., Sherman, L., McDermott, D. F., Haas, N. B., Flaherty, K. T., Ross, R., Eisenberg, P., Meltzer, P. S., Merino, M. J. & 3 others, Bottaro, D. P., Linehan, W. M. & Srinivasan, R., Jan 10 2013, In : Journal of Clinical Oncology. 31, 2, p. 181-186 6 p.

Research output: Contribution to journalArticle

279 Scopus citations
2012

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Grünwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J. P., Lee, S. H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., Romedi, M., Ferrandini, S. & 249 others, Rondinon, M., Pittman, K., Goldstein, D., Shapiro, J., Troon, S., Yip, D., Mainwaring, P., Zigeuner, R., Loidl, W., Greil, R. F., Schmidinger, M., De Grève, J., Rottey, S., Vermorken, J., Machiels, J., Gil, T., Gennigens, C., Roumeguere, T., Barrios, C., Mathias, C., Assi, H., Hotte, S., Karakiewicz, P., Knox, J., Spadafora, S., Wood, L., Zalewski, P., Mackensie, M., Bjarnason, G., Lalancette, A., Chan, A., Higgins, B., North, S., Soulieres, D., Asselah, J., Sperlich, C., Miller, W., Yadav, S., El-Maraghi, R., Godoy, J., Prausová, J., Katolicka, J., Petruzelka, L., Kiss, I., Bono, P., Lapela, M., Miller, K., Bergmann, L., Beck, J., Jäger, E., Kindler, M., Overkamp, F., Wirth, M., Hölzer, W., Gschwend, J., Stenzl, A., Gauler, T., Niederwieser, D., Marschner, N., Lück, A., Tessen, H., Eichelberg, C., Steiner, T., Goebell, P., Kettner, E., Bakhshandeh-Bath, A., Wilhelm, M., Schmitz, S., Jacob, A., Bierer, S., Kube, U., Staehler, M., Engel, E., Frambach, M., Schellenberger, U., Albers, P., Simon, J., Gleissler, M., Klotz, T., Repp, R., Kröning, H., Westermann, J., Rebmann, U., Brehmer, B., Niederle, N., Grund, C., Verpoort, K., Fonara, P., Rassweiler, J., Bamias, A., Fountzilas, G., Razis, E., Mouratidou, D., Georgoulias, V., Samantas, E., Bodrogi, I., Mangel, L., Szanto, J., Berger, R., Pe'er, A., Sella, A., Ben-Yosef, R., Nechushtan, H., Crinò, L., Bracarda, S., Ciuffreda, L., Graiff, C., Falcone, A., Roselli, M., Sternberg, C., Santoro, A., Ruggeri, E., Bearz, A., Venturini, M., Aglietta, M., Amadori, D., Di Costanzo, F., Bari, M., Gebbia, N., Conte, P., Bonetti, A., Bordonaro, R., Cascinu, S., Contu, A., Cruciani, G., Gasparro, D., Nardi, M., Lelli, G., Lo Re, G., Boccardo, F., Lorusso, V., Maiello, E., Manente, P., Passalacqua, R., Piantedosi, F., Porta, C., Sacco, C., Tondini, C., De Placido, S., Carteni, G., Dogliotto, L., Rosti, G., Milella, M., Roila, F., Amoroso, D., Farina, G., Al-Khatib, H., Lee, S., Kim, T., Ahn, J., Lim, H., Rha, S., Chung, I., Kim, J., Chung, J., Ghosn, M., Shameseddine, A., Lugo, R., Cabrera, P., Osanto, S., Groenewegen, G., Blank, C., van den Eertwegh, F., van Herpen, C., Oosting, S., Soetekouw, P., Lilleby, W., Klepp, O., Guren, T., Alcedo, J., Karlov, P., Nosov, D., Roman, L., Rusakov, I., Bazarbashi, S., Toh, C., Mardiak, J., Constenla, M., Solans, F. G. D. M., Maroto Ray, J., Bellmunt Mollins, J., Castellano, D., Duran Martinez, I., Mellado Gonzalez, B., Domenech Santasusana, M., Lopez-Brea Piqueras, M., Campillo Fuentes, J., Gonzalez Larriba, J., Luque Caro, R., Meana Garcia, A., Aparicio, L., Batista Lopez, N., Calderero Aragon, V., Valverde Morales, C., Figueiras, M., Contreras Ibanez, J., Gonzalez Billalabeitia, E., Estrada, E., Arranz, J., Lambea Sorrosal, J., Lozano, A., de Villena, M. C., Espinosa, E., Lopez, R., Perez Garcia, J., Laurell, A., Stierner, U., Cwikiel, M., Borner, M., Dietrich, P. Y., Rothermundt, C., Pu, Y., Chang, Y., Ou, Y., Chuang, C., Liao, Y., Srimuninnimit, V., Sriuranpong, V., Buyukberber, S., Yalcin, B., Goker, E., Yalcin, S., Geldart, T., Wagstaff, J., Nicholson, S., Chowdhury, S., Bahl, A., Jones, R., Azzabi, A., Chao, D., Fife, K., Hawkins, R., Mead, G., Nathan, P., Pandha, H., Hajdenberg, J., Gabrail, N., Nimeh, N., Logan, T., Flaig, T., Schraeder, R., Rini, B., O'Rourke, M., Alemany, C., Beck, J., Kessinger, A., Amin, A., Arriaga, M. & Rodriguez, J., Feb 2012, In : European Journal of Cancer. 48, 3, p. 324-332 9 p.

Research output: Contribution to journalArticle

77 Scopus citations

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

51 Scopus citations

Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., Richards, J., Michener, T., Balogh, A., Heller, K. N. & Hodi, F. S., May 1 2012, In : The lancet oncology. 13, 5, p. 459-465 7 p.

Research output: Contribution to journalArticle

633 Scopus citations

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

Ribas, A., Chesney, J. A., Gordon, M. S., Abernethy, A. P., Logan, T. F., Lawson, D. H., Chmielowksi, B., Glaspy, J. A., Lewis, K., Huang, B., Wang, E., Hsyu, P. H., Gomez-Navarro, J., Gerhardt, D., Marshall, M. A. & Gonzalez, R., Nov 21 2012, In : Journal of Translational Medicine. 10, 1, 236.

Research output: Contribution to journalArticle

30 Scopus citations
2011

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus

Maroto, J. P., Hudes, G., Dutcher, J. P., Logan, T. F., White, C. S., Krygowski, M., Cincotta, M., Shapiro, M., Duran, I. & Berkenblit, A., May 1 2011, In : Journal of Clinical Oncology. 29, 13, p. 1750-1756 7 p.

Research output: Contribution to journalArticle

89 Scopus citations
2010

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., Hammershaimb, L. & Kirkwood, J. M., Mar 15 2010, In : Cancer. 116, 6, p. 1526-1534 9 p.

Research output: Contribution to journalArticle

113 Scopus citations
2009

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma

Tarhini, A. A., Millward, M., Mainwaring, P., Kefford, R., Logan, T., Pavlick, A., Kathman, S. J., Laubscher, K. H., Dar, M. M. & Kirkwood, J. M., Feb 15 2009, In : Cancer. 115, 4, p. 859-868 10 p.

Research output: Contribution to journalArticle

48 Scopus citations

Prognostic Implications of Polymorphisms and Interleukin-2 Therapy for Renal Cell Carcinoma

Gardner, T. A. & Logan, T., Aug 1 2009, In : Journal of Urology. 182, 2, p. 425-426 2 p.

Research output: Contribution to journalEditorial

2008

A dose-escalation study of recombinant human Lnterleukin-18 using two different schedules of administration in patients with cancer

Robertson, M. J., Kirkwood, J. M., Logan, T. F., Koch, K. M., Kathman, S., Kirby, L. C., Bell, W. N., Weisenbach, J., Thurmond, L. M. & Dar, M. M., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3462-3469 8 p.

Research output: Contribution to journalArticle

63 Scopus citations

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II cytokine working group study

Atkins, M. B., Sosman, J. A., Agarwala, S., Logan, T., Clark, J. I., Ernstoff, M. S., Lawson, D., Dutcher, J. P., Weiss, G., Curti, B. & Margolin, K. A., Oct 15 2008, In : Cancer. 113, 8, p. 2139-2145 7 p.

Research output: Contribution to journalArticle

71 Scopus citations
2007

Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: A cytokine working group study

Clark, J. I., Mehrabi, J., Sosman, J. A., Logan, T. F., Margolin, K. A., Dutcher, J. P., Urba, W. J., Ernstoff, M. S., McDermott, D. F., Lau, A. M. & Atkins, M. B., Nov 2007, In : Journal of Immunotherapy. 30, 8, p. 839-846 8 p.

Research output: Contribution to journalArticle

6 Scopus citations

Sunitinib phase II study in patients with renal cell cancer: A commentary

Logan, T. F., Jan 1 2007, In : American Journal of Hematology/ Oncology. 6, 1, p. 21-23+27

Research output: Contribution to journalComment/debate

Urticaria and angioedema in renal cell cancer patients treated with IL-2

Logan, T. F., Strippoli, G. & Levine, M. I., Oct 1 2007, In : Cancer Investigation. 25, 7, p. 584-588 5 p.

Research output: Contribution to journalArticle

2006

Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study

Rini, B. I., Halabi, S., Barrier, R., Margolin, K. A., Avigan, D., Logan, T., Stadler, W. M., McCarthy, P. L., Linker, C. A. & Small, E. J., Jul 1 2006, In : Biology of Blood and Marrow Transplantation. 12, 7, p. 778-785 8 p.

Research output: Contribution to journalArticle

35 Scopus citations

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.

Robertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., Jewell, R. C., Bell, W. N., Thurmond, L. M., Weisenbach, J., Roberts, S. & Dar, M. M., Jul 15 2006, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 12, 14 Pt 1, p. 4265-4273 9 p.

Research output: Contribution to journalArticle

98 Scopus citations

Interleukins 18 and 21: Biology, mechanisms of action, toxicity, and clinical activity

Logan, T. F. & Robertson, M. J., Mar 1 2006, In : Current oncology reports. 8, 2, p. 114-119 6 p.

Research output: Contribution to journalReview article

7 Scopus citations
2005

Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma

Wagner, J. D., Schauwecker, D., Davidson, D., Logan, T., Coleman, J. J., Hutchins, G., Love, C., Wenck, S. & Daggy, J., Aug 1 2005, In : Cancer. 104, 3, p. 570-579 10 p.

Research output: Contribution to journalArticle

131 Scopus citations

Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies

Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., Ensor, C. M., Prestayko, A. W., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., Savaraj, N., Feun, L. G. & Logan, T. F., Dec 1 2005, In : Journal of Clinical Oncology. 23, 30, p. 7660-7668 9 p.

Research output: Contribution to journalArticle

174 Scopus citations

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P. G., Urba, W. J., Smith, J. W., Margolin, K. A., Mier, J. W., Gollob, J. A., Dutcher, J. P. & Atkins, M. B., Jan 1 2005, In : Journal of Clinical Oncology. 23, 1, p. 133-141 9 p.

Research output: Contribution to journalArticle

632 Scopus citations

Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma

Burczynski, M. E., Twine, N. C., Dukart, G., Marshall, B., Hidalgo, M., Stadler, W. M., Logan, T., Dutcher, J., Hudes, G., Trepicchio, W. L., Strahs, A., Immermann, F., Slonim, D. K. & Dorner, A. J., Feb 1 2005, In : Clinical Cancer Research. 11, 3, p. 1181-1189 9 p.

Research output: Contribution to journalArticle

101 Scopus citations
2004

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S. H., Marshall, B., Boni, J. P., Dukart, G. & Sherman, M. L., 2004, In : Journal of Clinical Oncology. 22, 5, p. 909-918 10 p.

Research output: Contribution to journalArticle

865 Scopus citations
2003

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial

Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., Flaherty, L., Sosman, J. A., Logan, T. F., White, R., Weiss, G. R., Redman, B. G., Tretter, C. P. G., McDermott, D., Smith, J. W., Gordon, M. S. & Margolin, K. A., Aug 15 2003, In : Journal of Clinical Oncology. 21, 16, p. 3133-3140 8 p.

Research output: Contribution to journalArticle

241 Scopus citations

Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma

Twine, N. C., Stover, J. A., Marshall, B., Dukart, G., Hidalgo, M., Stadler, W., Logan, T., Dutcher, J., Hudes, G., Dorner, A. J., Slonim, D. K., Trepicchio, W. L. & Burczynski, M. E., Sep 15 2003, In : Cancer Research. 63, 18, p. 6069-6075 7 p.

Research output: Contribution to journalArticle

114 Scopus citations

MAGE-6 encodes HLA-DRβ1*0401-presented Epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma

Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Brusic, V., Sidney, J., Sette, A., Logan, T. F., Kasamon, Y. L., Slingluff, C. L., Kirkwood, J. M. & Storkus, W. J., Mar 1 2003, In : Clinical Cancer Research. 9, 3, p. 947-954 8 p.

Research output: Contribution to journalArticle

55 Scopus citations

Nephrectomy for metastatic renal cell carcinoma: Indiana University experience

Mosharafa, A., Koch, M., Shalhav, A., Gardner, T., Logan, T., Bihrle, R. & Foster, R., Oct 1 2003, In : Urology. 62, 4, p. 636-640 5 p.

Research output: Contribution to journalArticle

18 Scopus citations

Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma

Wagner, J. D., Ranieri, J., Evdokimow, D. Z., Logan, T., Chuang, T. Y., Johnson, C. S., Jung, S. H., Wenck, S. & Coleman, J. J., Aug 1 2003, In : Plastic and reconstructive surgery. 112, 2, p. 486-497 12 p.

Research output: Contribution to journalArticle

65 Scopus citations
2002

Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial

Logan, T. F., Jadali, F., Egorin, M. J., Mintun, M., Sashin, D., Gooding, W. E., Choi, Y., Bishop, H., Trump, D. L., Gardner, D., Kirkwood, J., Vlock, D. & Johnson, C., Jan 1 2002, In : Cancer Chemotherapy and Pharmacology. 50, 6, p. 433-444 12 p.

Research output: Contribution to journalArticle

20 Scopus citations
2 Scopus citations

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

Zarour, H. M., Coval, K., Williams, E., Kirkwood, J. M., Maillere, B., Pouvelle-Moratille, S., Castelli, F., Brusic, V., Land, S., Bennouna, J. & Logan, T., Jan 1 2002, In : Cancer Research. 62, 1, p. 213-218 6 p.

Research output: Contribution to journalArticle

108 Scopus citations